SUNDAY, SEPTEMBER 25, 2016

Moderna, Institut Pasteur team up for disease research

Moderna Therapeutics and the Institut Pasteur said on Tuesday that they had created a long-term strategic research partnership focusing on the discovery and development of drugs and vaccines using Moderna's mRNA Therapeutics platform.

Valera, a Moderna venture, will manage the research collaboration for Moderna and will sponsor pre-clinical and clinical research programs at the Institut Pasteur that will identify and develop new approaches for battling known and emerging viral and bacterial diseases.

"We look forward to collaborating with Valera and to using Moderna's mRNA platform to discover and develop new vaccines and treatments to address infectious diseases in an entirely new way,” Institut Pasteur President Christian Brechot said. “This partnership will be a trump card in our fight against viral and bacterial disease."

Moderna President and CEO Stephane Bancel is excited about the new partnership with the Institut Pasteur.

"We are very honored to be working with the institute that Monsieur Louis Pasteur started more than 125 years ago in Paris,” Bancel said. “He is the father of the modern fight against infectious disease. Through our partnership with the Institut Pasteur, we will work with world-class researchers and clinicians who will be critical allies as we strive to develop a transformative approach to fighting infectious diseases for patients throughout the world. This agreement builds on our strategy of partnering with leaders in critical fields of medicine, from AstraZeneca, Alexion, Merck and DARPA to our recently announced collaboration with the Karolinska Institutet, to advance the development of mRNA-based drugs and vaccines across multiple therapeutic areas."

Louis Pasteur created the Institut Pasteur in 1887, and it has become world-renowned for its biomedical research.

Moderna is known for RNA Therapeutics, a new in vivo drug technology that produces human proteins, antibodies and novel proteins inside patient cells, which are in turn secreted or activated intracellularly.